Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2014; 49(3): 196-205
DOI: 10.1055/s-0034-1372235
Fachwissen
Anästhesiologie & Intensivmedizin Topthema: Neue direkte orale Antikoagulanzien (DOAK)
© Georg Thieme Verlag Stuttgart · New York

Perioperatives Management und Therapie von Blutungskomplikationen

Perioperative management and therapy of bleeding complications
Christian von Heymann
,
Lutz Kaufner
,
Mareike Körber
Further Information

Publication History

Publication Date:
07 April 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die neuen oralen Antikoagulanzien (DOAK) hemmen direkt Thrombin (Dabigatran, Pradaxa®) bzw. den aktivierten Faktor X (Rivaroxaban, Xarelto® und Apixaban, Eliquis®) und sind für die Thromboembolieprophylaxe nach Hüft- und Kniegelenksersatzoperationen und die Schlaganfallsprophylaxe bei nicht-valvulärem Vorhofflimmern zugelassen. Weitere Indikationen bestehen für Rivaroxaban (Xarelto) in der Behandlung der tiefen Bein-Venenthrombose, der Prävention der Lungenarterienembolie und der Antikoagulation nach Myokardinfarkt. Edoxaban (Lixiana®) erwartet als direkter FXa-Inhibitor seine Zulassung in Deutschland für die Indikation nicht valvuläres Vorhofflimmern im Jahr 2014. Bei vergleichbaren Halbwertszeiten von 8-17 Stunden erfolgt die Elimination für Dabigatran (Pradaxa) und Rivaroxaban (Xarelto) überwiegend renal, für Apixaban (Eliquis) zu 75% hepatisch und für Edoxaban (Lixiana®) zu 40% renal und zu 60% über die Faeces. Das Pausieren der direkten Antikoagulanzien vor einer Operation oder Intervention ist primär von der Nieren- bzw. Leberfunktion des Patienten bzw. dem Blutungsrisiko der Operation abhängig. Gegenüber den Vitamin K-Antagonisten Phenprocoumon (Marcumar®, Falithrom®) und Warfarin (Coumadin®) ist allgemein von kürzeren präoperativen Pausierungszeiten auszugehen. Für den Fall der akuten Blutung wird für den direkten Thrombininhibitor Dabigatran (Pradaxa) die Hämodialyse zur Elimination der Substanz empfohlen. Für die direkten FXa-Inhibitoren Rivaroxaban (Xarelto) und Apixaban (Eliquis) ist dies aufgrund der hohen Plasmaeiweißbindung nicht möglich. Für Edoxaban (Lixiana) sind hierzu keine Daten bekannt. Supportiv wird bei lebensbedrohlichen Blutungen die Substitution von Prothrombinkomplexpräparat (PPSB), welches die Faktoren II, VII, IX und X enthält, und in zweiter Linie die Gabe von aktivierten Faktorenkonzentraten wie rekombinanter aktivierter Faktor VII und aktiviertem Prothrombinkomplexpräparat empfohlen.

Summary

The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophylaxis after hip and knee replacement surgery and stroke prevention in non-valvular atrial fibrillation. Moreover, rivaroxaban has been approved for the treatment of deep venous thrombosis, prevention of pulmonary embolism and anticoagulation after acute myocardial infarction. The direct FXa-inhibitor edoxaban (Lixiana®) expects approval for the prevention of stroke in atrial fibrillation in Germany in 2014. The half lives of all direct anticoagulants range between 8 and 17 hours. Dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) are mainly excreted by the kidneys, apixaban (Eliquis®) by the liver (75%) and edoxaban (Lixiana®) by the kidneys (40%) and the faeces in 60%. Prior to surgery a shorter cessation is expected compared to the vitamin k antagonists phenprocoumon (Marcumar®, Falithrom®) and warfarin (Coumadin®). For acute bleedings caused by the direct thrombin inhibitor dabigatran (Pradaxa®) hemodialysis is recommended to eliminate the drug from the plasma. Due to the high protein binding the direkt FXa-inhibitors rivaroxaban (Xarelto®) and apixaban (Eliquis®) can not be hemodialysed. For edoxaban (Lixiana®) no data on elimination by renal replacement therapy are available. In case of life-threatening bleeding the replacement of a prothrombin complex preparation (PCC) containing the factors II, VII, IX and X and, second line, activated factor concentrates as recombinant factor VIIa or activated prothrombin complex preparations are recommended.

Kernaussagen

  • Bei der perioperativen Planung sind die Halbwertszeiten der direkten oralen Antikoagulanzien (DOAK) und das Vorliegen einer Nieren- oder Leberinsuffizienz entscheidend.

  • In Zulassungstudien zeigen die DOAK bisher keine erhöhte, sondern tendenziell eine niedrigere Inzidenz von Blutungen als Warfarin.

  • Das Blutungsrisiko hängt neben operationsspezifischen Aspekten von der Pharmakokinetik der Substanz sowie der Nieren- und Leberfunktion ab.

  • Bei aktiver Blutung unter DOAK ist der Einsatz von Aktivkohle bei 2–3 h zurückliegender Einnahme von DOAK noch sinnvoll; eine Magenspülung zeigt wahrscheinlich – wenn überhaupt – nur innerhalb der ersten Stunde nach Einnahme Wirkung. Zu Frischplasma und Tranexamsäure ist beim gegenwärtigen Forschungsstand keine eindeutige Aussage möglich.

  • Derzeit liegt für keines der zugelassenen DOAK ein direktes und spezifisches Antidot vor. Gegeben werden können nur Gerinnungsfaktorenkonzentrate zur Substitution. Dabei ist jedoch eine hämostaseologische Beratung dringend zu empfehlen.

Schlüsselwörter:

Blutungskomplikationen - neue direkte orale Antikoagulanzien - Dabigatran - Apixaban - Edoxaban - Rivaroxaban

Key words:

new oral anticoagulants - bleeding complications - dabigatran - apixaban - edoxaban - rivaroxaban

Ergänzendes Material

 

  • Literaturverzeichnis

  • 1 Borris LC. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Arch Orthop Trauma Surg 2010; 130: 583-589
    CrossrefPubMedGoogle Scholar
  • 2 Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815
    CrossrefPubMedGoogle Scholar
  • 3 Lassen MR, Raskob GE, Gallus A et al. ADVANCE-3 investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement (ADVANCE-3). N Engl J Med 2010; 363: 2487-2498
    CrossrefPubMedGoogle Scholar
  • 4 Patel MR, Maheffey KW, Garg J et al. Rocket AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 5 Conolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 6 Granger CB, Alexander JH, McMurray JJ et al. ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992
    CrossrefPubMedGoogle Scholar
  • 7 EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med 2010; 363: 2499-2510
    CrossrefPubMedGoogle Scholar
  • 8 EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012; 366: 1287-1297
    CrossrefPubMedGoogle Scholar
  • 9 Giugliano RP, Ruff CT, Braunwald E et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013; 369: 2093-104
    CrossrefPubMedGoogle Scholar
  • 10 Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in developement. Clin Pharmacokinet 2009; 48: 1-22
    CrossrefPubMedGoogle Scholar
  • 11 Fachinformation Pradaxa® 110 mg Hartkapseln, Boehringer Ingelheim. Juli 2013 2013
    PubMedGoogle Scholar
  • 12 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmakokinet 2008; 47: 285-295
    PubMedGoogle Scholar
  • 13 Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268
    CrossrefPubMedGoogle Scholar
  • 14 Fachinformation Xarelto® 10 mg, Bayer Vital GmbH. Juni 2013 2013
    PubMedGoogle Scholar
  • 15 Cabral KP. Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis 2013; 36: 133-140
    CrossrefPubMedGoogle Scholar
  • 16 Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81
    CrossrefPubMedGoogle Scholar
  • 17 Fachinformation Eliquis® 5 mg, Bristol Myers Squibb Pfizer. Februar 2013 2013
    PubMedGoogle Scholar
  • 18 Lassen MR, Raskob GE, Gallus A et al. Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement. N Engl J Med 2009; 361: 594-604
    CrossrefPubMedGoogle Scholar
  • 19 Ogata K, Mendell-Harary J, Tachibana M et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics oft he Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J Clin Pharmacol 2010; 50: 743-745
    CrossrefPubMedGoogle Scholar
  • 20 Ahrens I, Bode C. Oral anticoagulation with edoxaban. Hämostaseologie 2012; 32: 212-215
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Bathala MS, Masumoto H, Oguma T et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012; 40: 2250-2255
    CrossrefPubMedGoogle Scholar
  • 22 Friedman RJ, Dahl OE, Rosencher N et al. RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010; 126: 175-182
    CrossrefPubMedGoogle Scholar
  • 23 Eriksson BI, Borris LC, Friedman RJ et al. RECORD 1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775
    CrossrefPubMedGoogle Scholar
  • 24 Eriksson BI, Dahl OE, Rosencher N et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956
    CrossrefPubMedGoogle Scholar
  • 25 Koscielny J, Beyer-Westendorf J, von Heymann C et al. Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis]. Hamostaseologie 2012; 32: 287-293
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Spannagl M, Bauersachs R, Debus ES et al. Dabigatran therapy--perioperative management and interpretation of coagulation tests]. Hamostaseologie 2012; 32: 294-305
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Sié P, Samama CM, Godier A et al. Working Group on Perioperative Haemostasis, French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011; 104: 669-676
    CrossrefPubMedGoogle Scholar
  • 28 Palareti G. Anticoagulation for venous thromboembolism: what if they bleed?. Hamostaseologie 2012; 32: 40-44
    PubMedGoogle Scholar
  • 29 Healey JS, Eikelboom J, Douketis J et al. RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-8
    CrossrefPubMedGoogle Scholar
  • 30 Hokusai-VTE Investigators. Büller HR, Décousus H, Grosso MA et al. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med 2013; 369: 1406-1415
    CrossrefPubMedGoogle Scholar
  • 31 Giugliano RP, Ruff CT, Braunwald E et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
    CrossrefPubMedGoogle Scholar
  • 32 Connolly SJ, Eikelboom J, Joyner C et al. AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2011; 364: 806-817
    CrossrefPubMedGoogle Scholar
  • 33 FDA, Department of Health and Human Services: Clinical Review NDA 22-512: Pradaxa® (Dabigatran). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugs AdvisoryCommittee/UCM247244.pdf
    PubMedGoogle Scholar
  • 34 Dager WE. Developing a management plan for oral anticoagulant reversal. Am J Health Syst Pharm 2013; (Suppl. 01) 70: 21-31
    CrossrefPubMedGoogle Scholar
  • 35 Gogarten W, Vandermeulen E, Van Aken H et al. European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 999-1015
    CrossrefPubMedGoogle Scholar
  • 36 Lindhoff-Last E, Samama MM, Ortel TL et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-679
    CrossrefPubMedGoogle Scholar
  • 37 Baglin T. The role oft he laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013; 11 (Suppl. 01) 122-128
    CrossrefPubMedGoogle Scholar
  • 38 Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87: 141-145
    CrossrefPubMedGoogle Scholar
  • 39 Woo JS, Kapadia N, Phanco SE et al. Positive outcome after intentional overdose of dabigatran. J Med Toxicol 2013; 9: 192-195
    CrossrefPubMedGoogle Scholar
  • 40 Chowdury P, Saayman AG, Paulus U et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2001; 125: 69-73
    PubMedGoogle Scholar
  • 41 Alikhan R, Rayment R, Keeling D et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J [Epub ahead of print] 2013;
    PubMedGoogle Scholar
  • 42 Zhou W, Schwarting S, Illanes S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599
    CrossrefPubMedGoogle Scholar
  • 43 Peacock WF, Gearhart MM, Mills RM. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol 2012; 35: 730-737
    CrossrefPubMedGoogle Scholar
  • 44 CRASH-2 trial collaborators. Shakur H, Roberts I, Bautista R et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32
    CrossrefPubMedGoogle Scholar
  • 45 Clavé A, Fazilleau F, Dumser D, Lacroix J. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients. Orthopaedics & Traumatology: Surgery & Research 2012; 98: 484-490
    CrossrefPubMedGoogle Scholar
  • 46 Perzborn E, Gruber A, Tinel H et al. Reversal of rivaroxaban anticoagulation by hemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Körber MK, Langer E, Ziemer S et al. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost Epub ahead of print 2013;
    PubMedGoogle Scholar
  • 48 Eerenberg ES, Kaphuisen PW, Meertien KS. Reversal rivaroxaban and dabigatran by prothrombin complex concentrate – a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579
    CrossrefPubMedGoogle Scholar
  • 49 Pragst I, Zeitler SH, Doerr B et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841-1848
    CrossrefPubMedGoogle Scholar
  • 50 Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013; 8
    PubMedGoogle Scholar
  • 51 Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Kozek-Langenecker SA, Afshari A, Albaladejo P et al. Management of severe perioperative bleeding Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382
    CrossrefPubMedGoogle Scholar
  • 53 Choi S, Douketis JD. Management of patients who are receiving warfarin or a new oral anticoagulant and require urgent or emergency surgery. Pol Arch Med Wewn 2012; 122: 437-442
    PubMedGoogle Scholar
  • 54 Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451
    CrossrefPubMedGoogle Scholar
  • 55 van Ryn J, Stangier J, Haertter S. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Godier A, Miclot A, Le Bonniec B et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102
    CrossrefPubMedGoogle Scholar